Xeris Biopharma Holdings, Inc.

XERS· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$8.13+0.62%

2026-08-03

Financials

Valuation Metrics

Xeris Biopharma Holdings, Inc.'s Market Cap is $1.40B. At end of 2025 it was $1.30B. Ranked #2282 of 3,111 in US market (top 73%), #912 of 1,445 on NASDAQ (top 63%), #171 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 64%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$1.40B	US#2,282/3,111 Sec#171/269
Revenue	$315M	US#2,539/3,111 Sec#95/269
Net Income	$12M	US#2,134/3,111 Sec#73/269
Total Assets	$392M	US#2,845/3,111 Sec#191/269
Net Assets	$13M	US#2,996/3,111 Sec#258/269
Value
P/E	116.89x	US#2,086/3,111 Sec#68/269
P/B	107.88x	US#2,966/3,111 Sec#259/269
P/S	4.46x	US#2,183/3,111 Sec#70/269
EV/EBITDA	28.82x	US#2,150/3,111 Sec#66/269
FCF Yield	3.36%	US#1,689/3,111 Sec#55/269
Profitability
ROE	92.29%	US#39/3,111 Sec#4/269
ROA	3.06%	US#1,390/3,111 Sec#62/269
Op. Margin	11.40%	US#1,521/3,111 Sec#64/269
Revenue Growth	38.27%	US#397/3,111 Sec#63/269
Financial Health
Debt Ratio	2912.94%	US#2,951/3,111 Sec#262/269
Total Debt	$37M	US#2,628/3,111 Sec#160/269
FCF	$47M	US#1,950/3,111 Sec#71/269
Cash	$112M	US#2,162/3,111 Sec#171/269
Current Ratio	2.12x	US#1,177/3,111 Sec#225/269
Net Debt/EBITDA	-1.61x	US#217/3,111 Sec#16/269
Performance
1Y Return	51.12%	US#590/3,111 Sec#112/269
1M Return	-1.81%	US#1,385/3,111 Sec#90/269
From 52W High	-19.35%	US#1,657/3,111 Sec#113/269
1Y MDD	-46.57%	US#2,261/3,111 Sec#174/269
Trading
Volume	1,928,832 shares	US#1,016/3,111 Sec#93/269
Trading Value	$16M	US#2,175/3,111 Sec#174/269
Per Share
BPS	$0.08	US#2,724/3,111 Sec#233/269